TVRD (Cara Therapeutics Inc) Short-Term Debt to Capital

Cara Therapeutics Inc (TVRD) develops specialized treatments for kidney-related pruritus by leveraging the development of selective agonists. This price chart shows that shares correlate with clinical trial success and available capital, where the indicator stands at 0.02. The company is currently optimizing expenses and revising its research plan following a series of setbacks during the final stages of new molecule development.

This ratio measures the proportion of liabilities maturing within one year relative to equity, determining the issuer's current financial stability. The metric allows an investor to assess liquidity risk and the company's dependence on immediate refinancing. The trend of short-term loans to equity reflects the balance between leveraged growth and solvency. For Cara Therapeutics Inc (TVRD), such a debt structure is acceptable provided there is a stable cash flow from long-term sales of the patented drug.